VJVirtual | Approval of aducanumab for Alzheimer’s disease

Aducanumab was granted accelerated approval on June 7 by the U.S. Food and Drug Administration (FDA). Wiesje van der Flier, PhD, VU University Medical Center, Amsterdam, The Netherlands, discusses the landmark approval of aducanumab, a monoclonal antibody that targets the amyloid-beta protein, for the treatment of early Alzheimer’s disease. This interview took place during the European Academy of Neurology 2021 congress.